We Offer Worldwide Shipping
Login Wishlist

Oxaliplatin

$78

  • Brand : BIOFRON

  • Catalogue Number : BF-O2009

  • Specification : 98%

  • CAS number : 61825-94-3

  • Formula : C8H14N2O4Pt

  • Molecular Weight : 397.29

  • PUBCHEM ID : 9887053

  • Volume : 20mg

In stock

Quantity
Checkout Bulk Order?

Catalogue Number

BF-O2009

Analysis Method

HPLC,NMR,MS

Specification

98%

Storage

2-8°C

Molecular Weight

397.29

Appearance

Powder

Botanical Source

synthesis

Structure Type

Others

Category

Standards;Natural Pytochemical;API

SMILES

C1CCC(C(C1)N)N.C(=O)(C(=O)[O-])[O-].[Pt+2]

Synonyms

Dacplat/Oxaliplatin/platinum, [ethanedioato(2-)-κO,κO]-, compd. with (1R,2R)-1,2-cyclohexanediamine (1:1)/Platinum(2+) ethanedioate - (1R,2R)-1,2-cyclohexanediamine (1:1)/Platinum(2+) ethanedioate (1R,2R)-1,2-cyclohexanediamine (1:1)/[Ethanedioato(2-)-κO,O]platinum - (1R,2R)-cyclohexane-1,2-diamine (1:1)/Platinum(2+) ethanedioate (1R,2R)-1,2-cyclohexanediamine (1:1:1)/Elocatin

IUPAC Name

[(1R,2R)-2-azanidylcyclohexyl]azanide;oxalic acid;platinum(2+)

Density

Solubility

Flash Point

Boiling Point

193.6ºC at 760 mmHg

Melting Point

InChl

InChl Key

WGK Germany

RID/ADR

HS Code Reference

2843900000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:61825-94-3) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

PMID

30682002

Abstract

BACKGROUND:
Oxaliplatin is used extensively for the treatment of gastrointestinal cancer and other malignancies, with increased frequency of use in recent years. Hypersensitivity reactions (HSRs) can pose a major problem in clinical practice because they can limit the use of oxaliplatin in the care of malignancies in which it has proven efficacy. Nurses play an integral role in the administration of oxaliplatin; therefore, they need to be well educated in the prevention, detection, and management of HSRs.

OBJECTIVES:
This article reviews the symptoms of HSRs associated with oxaliplatin, the specific management of HSRs associated with oxaliplatin, the role of desensitization, and the potential use of skin testing to better identify patients at risk for HSR.

METHODS:
This article reviews the literature related to the diagnosis, prevention, and management of HSRs associated with oxaliplatin and outlines nurses’ role.

FINDINGS:
Oxaliplatin HSRs can occur at any cycle, but patients are at highest risk after they have received six prior infusions of oxaliplatin.

KEYWORDS

hypersensitivity reaction; infusion reaction; oxaliplatin

Title

Oxaliplatin: Detection and Management of Hypersensitivity Reactions.

Author

Rogers BB1, Cuddahy T1, Briscella C1, Ross N1, Olszanski AJ1, Denlinger CS1.

Publish date

2019 Feb 1

PMID

30305703

Abstract

Oxaliplatin induced peripheral neurotoxicity is characterized by an acute cold-induced syndrome characterized by cramps, paresthesias/dysesthesias in the distal limbs and perioral region, that develops rapidly and lasts up to one week affecting nearly all the patients as well as by long-lasting symptoms. It has been previously shown that pharmacological or genetic ablation of TRPA1 responses reduces oxaliplatin-induced peripheral neurotoxicity in mouse models. In the present report, we show that treatment with concentrations of oxaliplatin similar to those found in plasma of treated patients leads to an acidification of the cytosol of mouse dorsal root ganglia neurons in culture and this in turn is responsible for sensitization of TRPA1 channels, thereby providing a mechanistic explanation to toxicity of oxaliplatin. Reversal of the acidification indeed leads to a significantly reduced activity of TRPA1 channels. Last, acidification occurs also in vivo after a single injection of therapeutically-relevant doses of oxaliplatin.

Title

Oxaliplatin induces pH acidification in dorsal root ganglia neurons.

Author

Riva B1, Dionisi M1, Potenzieri A1, Chiorazzi A2, Cordero-Sanchez C1, Rigolio R2, Carozzi VA2,3, Lim D1, Cavaletti G2, Marmiroli P2, Distasi C1, Genazzani AA4.

Publish date

2018 Oct 10

PMID

29247488

Abstract

Oxaliplatin (OXA), is a third generation platinum drug used as first-line chemotherapy in colorectal cancer (CRC). Cancer cells acquires resistance to anti-cancer drug and develops resistance. ATP-binding cassette (ABC) drug transporter ABCG2, one of multidrug resistance (MDR) protein which can effectively discharge a wide spectrum of chemotherapeutic agents out of cancer cells and subsequently reduce the intracellular concentration of these drugs. Role of ABCG2 and plausible molecular signaling pathways involved in Oxaliplatin-Resistant (OXA-R) colon cancer cells was evaluated in the present study. OXA resistant LoVo cells was developed by exposing the colon cells to OXA in a dose-dependent manner. Development of multi drug resistance in OXA-R cells was confirmed by exposing the resistance cells to oxaliplatin, 5-FU, and doxorubicin. OXA treatment resulted in G2 phase arrest in parental LoVo cells, which was overcome by OXA-R LoVo cells. mRNA and protein expression of ABCG2 and phosphorylation of NF-κB was significantly higher in OXA-R than parental cells. Levels of ER stress markers were downregulated in OXA-R than parental cells. OXA-R LoVo cells exposed to NF-κB inhibitor QNZ effectively reduced the ABCG2 and p-NF-κB expression and increased ER stress marker expression. On other hand, invasion and migratory effect of OXA-R cells were found to be decreased, when compared to parental cells. Metastasis marker proteins also downregulated in OXA-R cells. ABCG2 inhibitor verapamil, downregulate ABCG2, induce ER stress markers and induces apoptosis. In vivo studies in nude mice also confirms the same.

© 2017 Wiley Periodicals, Inc.

KEYWORDS

ABCG2; cancer stem cell; colon cancer; multi drug resistance; oxaliplatin

Title

Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis.

Author

Hsu HH1,2, Chen MC3, Baskaran R4, Lin YM5,6, Day CH7, Lin YJ8, Tu CC9, Vijaya Padma V10, Kuo WW11, Huang CY8,12,13.

Publish date

2018 Jul


Description :

Oxaliplatin is a DNA synthesis inhibitor. It causes DNA crosslinking damage, prevents DNA replication and transcription and causes cell death.